ArticleScientific reports2015
Epigenetic biomarker to support classification into pluripotent and non-pluripotent cells.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 53 citations in OpenAlex.
- NSD1 governs H3K36me2-mediated DNA methylation and drives endo-mesodermal differentiation of human iPSCs.Clinical epigenetics · 2026Article
- Reassessment of marker genes in human induced pluripotent stem cells for enhanced quality control.Nature communications · 2024Article
- Cardiac glycosides restore autophagy flux in an iPSC-derived neuronal model of WDR45 deficiency.bioRxiv : the preprint server for biology · 2024Article
- Automated high-content imaging in iPSC-derived neuronal progenitors.SLAS discovery : advancing life sciences R & D · 2023Article
- Epigenetic biomarkers to track differentiation of pluripotent stem cells.Stem cell reports · 2023Article
- CTCF deletion alters the pluripotency and DNA methylation profile of human iPSCs.Frontiers in cell and developmental biology · 2023Article
- Variation of DNA methylation on theRegenerative therapy · 2022Article
- Article
- Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation.BMC biology · 2022Article
- Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism.Science translational medicine · 2021Article
- Human Cell Atlas and cell-type authentication for regenerative medicine.Experimental & molecular medicine · 2020Review
- PRDM8 reveals aberrant DNA methylation in aging syndromes and is relevant for hematopoietic and neuronal differentiation.Clinical epigenetics · 2020Article
- Prediction model construction of mouse stem cell pluripotency using CpG and non-CpG DNA methylation markers.BMC bioinformatics · 2020Article
- Genetic barcoding reveals clonal dominance in iPSC-derived mesenchymal stromal cells.Stem cell research & therapy · 2020Article
- Senescence-Associated Metabolomic Phenotype in Primary and iPSC-Derived Mesenchymal Stromal Cells.Stem cell reports · 2020Article
- The StemCellFactory: A Modular System Integration for Automated Generation and Expansion of Human Induced Pluripotent Stem Cells.Frontiers in bioengineering and biotechnology · 2020Article
- Differentiation of Induced Pluripotent Stem Cells towards Mesenchymal Stromal Cells is Hampered by Culture in 3D Hydrogels.Scientific reports · 2019Article
- Article
- Tracking of epigenetic changes during hematopoietic differentiation of induced pluripotent stem cells.Clinical epigenetics · 2019Article
- Interrupted reprogramming into induced pluripotent stem cells does not rejuvenate human mesenchymal stromal cells.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quality control of human induced pluripotent stem cells (iPSCs) can be performed by several methods. These methods are usually relatively labor-intensive, difficult to standardize, or they do not facilitate reliable quantification. Here, we describe a biomarker to distinguish between pluripotent and non-pluripotent cells based on DNA methylation (DNAm) levels at only three specific CpG sites. Two of these CpG sites were selected by their discriminatory power in 258 DNAm profiles - they were either methylated in pluripotent or non-pluripotent cells. The difference between these two β-values provides an Epi-Pluri-Score that was validated on independent DNAm-datasets (264 pluripotent and 1,951 non-pluripotent samples) with 99.9% specificity and 98.9% sensitivity. This score was complemented by a third CpG within the gene POU5F1 (OCT4), which better demarcates early differentiation events. We established pyrosequencing assays for the three relevant CpG sites and thereby correctly classified DNA of 12 pluripotent cell lines and 31 non-pluripotent cell lines. Furthermore, DNAm changes at these three CpGs were tracked in the course of differentiation of iPSCs towards mesenchymal stromal cells. The Epi-Pluri-Score does not give information on lineage-specific differentiation potential, but it provides a simple, reliable, and robust biomarker to support high-throughput classification into either pluripotent or non-pluripotent cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.